Carregant...
Optimizing Early “Go/No Go” Decisions in CNS Drug Development
Go/No Go decisions concerning development of any single compound determine investment in increasingly costly studies from Phase 1–3. Such decisions are problematic for CNS drug development where the variety of molecular targets in the brain have stimulated decades of studies without major therapeuti...
Guardat en:
| Publicat a: | Expert Rev Clin Pharmacol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4648539/ https://ncbi.nlm.nih.gov/pubmed/25537256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17512433.2015.991715 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|